Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PNMT | P11086 | 6/20 | 0.36 |
| ▸ | CD44 | P16070 | 2/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | ASIC3 | Q9UHC3 | 2/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1593106 | 0.85 | HTR2C (0.41) | PNMTCD44MAOBHTR2CASIC3 | |
| SCHEMBL1482248 | 0.82 | — | — | |
| SCHEMBL159386 | 0.71 | CDK5 (0.33) | ADRA2AADRA2BADRA2C | |
| SCHEMBL558013 | 0.71 | — | — | |
| SCHEMBL4148663 | 0.69 | CDK5 (0.32) | — | |
| SCHEMBL611712 | 0.69 | PNMT (0.41) | PNMTCD44MAOBHTR2CCYP3A4 | |
| SCHEMBL21591624 | 0.67 | PNMT (0.42) | PNMTCD44MAOBASIC3ADRA2A | |
| SCHEMBL21591683 | 0.67 | PNMT (0.42) | PNMTCD44MAOBASIC3ADRA2A | |
| SCHEMBL160968 | 0.67 | POLB (0.43) | POLBSMN1; SMN2PNMTCD44MAOB | |
| SCHEMBL29772412 | 0.67 | POLB (0.43) | POLBSMN1; SMN2PNMTCD44MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 453 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713327-B2 | Heteroaryl heterocyclyl compounds for the treatment of autoimmune disease | HOFFMANN-LA ROCHE INC. (US) | 2023-08-01 | — | — | US | claimed |
| WO-2023081809-A1 | TRANS-CYCLOOCTENE-MODIFIED BISPECIFIC ANTIBODIES | TAMBO, INC. (US) | 2023-05-11 | — | — | WO | claimed |
| WO-2023077129-A1 | TETRAZINE CONJUGATES FOR IN VIVO TARGETED DELIVERY OF A PAYLOAD | TAMBO, INC. (US) | 2023-05-04 | — | — | WO | claimed |
| US-20210300947-A1 | NOVEL HETEROARYL HETEROCYCLYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2021-09-30 | — | — | US | claimed |
| EP-3807270-A1 | NOVEL HETEROARYL HETEROCYCLYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2021-04-21 | — | — | EP | claimed |
| CN-112313228-A | Novel heteroaryl heterocyclyl compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2021-02-02 | — | — | CN | claimed |
| WO-2019238616-A1 | NOVEL HETEROARYL HETEROCYCLYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2019-12-19 | — | — | WO | claimed |
| US-20150025058-A1 | 8 - SUBSTITUTED 2 -AMINO - [1,2,4] TRIAZOLO [1, 5 -A] PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2015-01-22 | — | — | US | claimed |
| EP-2817310-A1 | 8 - SUBSTITUTED 2 -AMINO - [1,2,4]TRIAZOLO [1, 5 -A]PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS | Merck Patent GmbH (DE) | 2014-12-31 | — | — | EP | claimed |
| US-20140228340-A1 | BENZONITRILE DERIVATIVES AS KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2014-08-14 | — | — | US | claimed |
| EP-1337271-A2 | COMBINATION OF GABA AGONISTS AND SORBITOL DEHYDROGENASE INHIBITORS | Pfizer Products Inc. (US) | 2003-08-27 | — | — | EP | claimed |
| US-6602875-B2 | Sorbitol dehydrogenase inhibitors | PFIZER INC | 2003-08-05 | — | — | US | claimed |
| EP-1326591-A2 | COMBINATION OF STATINS AND SORBITOL DEHYDROGENASE INHIBITORS | Pfizer Products Inc. (US) | 2003-07-16 | — | — | EP | claimed |
| US-6544998-B2 | For treatment of suffering from diabetic complications like diabetic neuropathy, nephropathy, cardiomyopathy, retinopathy, microangiopathy, macroangiopathy, cataracts and foot ulcers. | PFIZER INC | 2003-04-08 | — | — | US | claimed |
| US-20030065179-A1 | Sorbitol dehydrogenase inhibitors | CHU-MOYER MARGARET Y (US) | 2003-04-03 | — | — | US | claimed |
| US-20020091128-A1 | Combination of gaba agonists and sorbitol dehydrogenase inhibitors | MYLARI BANAVARA L (US) | 2002-07-11 | — | — | US | claimed |
| WO-2002043762-A2 | COMBINATION OF GABA AGONISTS AND SORBITOL DEHYDROGENASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2002-06-06 | — | — | WO | claimed |
| WO-2002032411-A2 | COMBINATION OF STATINS AND SORBITOL DEHYDROGENASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2002-04-25 | — | — | WO | claimed |
| EP-1185275-A1 | AMINOPYRIMIDINES AS SORBITOL DEHYDROGENASE INHIBITORS | Pfizer Products Inc. (US) | 2002-03-13 | — | — | EP | claimed |
| WO-2000059510-A1 | AMINOPYRIMIDINES AS SORBITOL DEHYDROGENASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-10-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228340-A1 | BENZONITRILE DERIVATIVES AS KINASE INHIBITORS | TBK1, NFKBIA, IKBKG | POLB 1155/4885SMN1; SMN2 2989/4885PNMT 3664/4885 |
| US-11713327-B2 | Heteroaryl heterocyclyl compounds for the treatment of autoimmune disease | SSB, UACA, HLA-DRB1 | POLB 1966/4885SMN1; SMN2 2573/4885PNMT 4266/4885 |
| US-20210300947-A1 | NOVEL HETEROARYL HETEROCYCLYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | SSB, UACA, HLA-DRB1 | POLB 2491/4885SMN1; SMN2 2864/4885PNMT 4607/4885 |
| US-20150025058-A1 | 8 - SUBSTITUTED 2 -AMINO - [1,2,4] TRIAZOLO [1, 5 -A] PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS | SYK, EIF2AK4, BTK | POLB 3864/4885SMN1; SMN2 4392/4885PNMT 3373/4885 |
| US-20030065179-A1 | Sorbitol dehydrogenase inhibitors | SLC5A1, SORD, SLC5A2 | POLB 4044/4885SMN1; SMN2 539/4885PNMT 2759/4885 |
| US-20020091128-A1 | Combination of gaba agonists and sorbitol dehydrogenase inhibitors | SORD, GABRE, SLC6A1 | POLB 2830/4885SMN1; SMN2 295/4885PNMT 3830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.